Understand the source comparison
Comparison: Thymalin Dosing Protocols Across Research Applications
Standard Immune Regulation 10mg IM Every 3 days 10 injections (30 days) T-lymphocyte count, CD4+/CD8+ ratio Most widely validated protocol in clinical literature. Balances efficacy with minimal receptor desensitisation risk Immune Senescence (Age 65+) 15mg IM
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Standard Immune Regulation
- 10mg IM
- Every 3 days
- 10 injections (30 days)
- T-lymphocyte count, CD4+/CD8+ ratio
- Most widely validated protocol in clinical literature. Balances efficacy with minimal receptor desensitisation risk
- Immune Senescence (Age 65+)
- 15mg IM
- Every 4 days
- 10 injections (40 days)
- Thymic output (TREC levels), NK-cell activity
- Higher dose compensates for age-related thymic involution. Interval extension prevents saturation
- Autoimmune Regulation
- Every 5 days
- 12 injections (60 days)
- Regulatory T-cell (Treg) populations, cytokine profile
- Longer intervals support Treg modulation without overstimulating effector T-cells. Used in experimental autoimmune protocols
- Post-Viral Recovery
- 7 injections (21 days)
- CD8+ cytotoxic T-cells, interferon-gamma production
- Shorter cycle targets acute immune reconstitution. Used in studies on post-infection immune dysfunction
- The standard 10mg every 3 days protocol represents the clinical baseline. It's the dosing structure with the most published evidence and the clearest safety profile. Deviations from this baseline (higher dose, longer intervals, extended cycles) should be justified by specific immune markers being targeted, not by a belief that more peptide equals better results.